In yesterday’s Wall Street session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares traded at $9.03, down -3.53% from the previous session.
RXRX stock price is now -1.09% away from the 50-day moving average and 1.01% away from the 200-day moving average. The market capitalization of the company currently stands at $2.14B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc (NASDAQ: RXRX). On March 16, 2023, Needham recently initiated its ‘Buy’ rating on the stock quoting a target price of $17, while ‘KeyBanc Capital Markets’ rates the stock as ‘Overweight’
In other news, Borgeson Blake, Director sold 20,054 shares of the company’s stock on May 14 ’24. The stock was sold for $202,934 at an average price of $10.12. Upon completion of the transaction, the Director now directly owns 7,198,360 shares in the company, valued at $65.0 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 02 ’24, Chief Executive Officer Gibson Christopher sold 50,000 shares of the business’s stock. A total of $423,500 was realized by selling the stock at an average price of $8.47. This leaves the insider owning 834,820 shares of the company worth $7.54 million. A total of 31.70% of the company’s stock is owned by insiders.
During the past 12 months, Recursion Pharmaceuticals Inc has had a low of $4.97 and a high of $16.75. As of last week, the company has a debt-to-equity ratio of 0.13, a current ratio of 4.65, and a quick ratio of 4.65. The fifty day moving average price for RXRX is $9.0904 and a two-hundred day moving average price translates $8.927025 for the stock.
The latest earnings results from Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at -0.38, missing analysts’ expectations of -0.37 by -0.01. This compares to -$0.34 EPS in the same period last year. The net profit margin was -765.90% and return on equity was -85.19% for RXRX. The company reported revenue of $13.79 million for the quarter, compared to $12.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 13.68 percent. For the current quarter, analysts expect RXRX to generate $13.75M in revenue.
